| Assessment Status | Rapid Review Complete |
| HTA ID | 24023 |
| Drug | Iptacopan |
| Brand | Fabhalta® |
| Indication | Iptacopan is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemolytic anaemia. |
| Assessment Process | |
| Rapid review commissioned | 04/06/2024 |
| Rapid review completed | 16/07/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical and cost effectiveness of iptacopan compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
